DENVER, March 15, 2023 /CNW/ – Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, today announced that it has entered into a third […]
- March 2023
- We investigate a lawsuit filed by Reunion Neuroscience that alleges Mindset Pharma “copied” its RE104 compound. Will this lawsuit, viewed by some as “a desperation move”, lead to a reunion with karma?
- ENGLEWOOD CLIFFS, NJ, March 15, 2023 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has achieved positive results for its toxicology study of SP-26, its novel time-released, dosage-controlled formulation of ketamine. The study results evaluated the […]
- TORONTO, March 15, 2023 (GLOBE NEWSWIRE) — Field Trip Health & Wellness Ltd. (TSX-V: FTHW) (“Field Trip” or the “Company”) today announced that, in an effort to reduce expenditures and preserve capital, it will be closing the Field Trip Health Centres located in Chicago, Washington DC, Seattle, San Diego and Fredericton. The anticipated last day […]
- The clinical trial will study PEX010, Filament’s botanical psilocybin drug candidate VANCOUVER, BC, March 15, 2023 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical–stage natural psychedelic drug development company, today announced approval from the United States Food and Drug Administration (FDA) for a clinical trial at the […]
- No more posts to load